(VAXR) - Company must regain compliance with the Nasdaq Bid Price Rule on or before the October 17, 2025 deadline -
Related Questions
How will the extension affect Vaxart's liquidity and short‑term price movement?
What specific measures is Vaxart implementing to meet the Nasdaq Bid Price Rule by the Oct 17, 2025 deadline?
How does this compliance situation compare to similar cases among peer biotech companies and what could it mean for long‑term investor confidence?